Athena Athena

X
[{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Announces Rare Pediatric Disease Designation for ATR-12 for the Treatment of Netherton Syndrome","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Preclinical"},{"orgOrder":0,"company":"Azitra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Azitra Awarded U.S. Composition of Matter Patent Covering Engineered Bacterial Strains for Treating Skin Conditions","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I"},{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Pricing of Initial Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Closing of Initial Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I"},{"orgOrder":0,"company":"Azitra","sponsor":"ThinkEquity","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"Azitra, Inc. Announces Pricing of Public Offering","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Azitra

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The company intends to use the net proceeds for clinical trials and product development of ATR12-351 (ATR-12) for the treatment of Netherton Syndrome.

            Lead Product(s): ATR-12

            Therapeutic Area: Rare Diseases and Disorders Product Name: ATR12-351

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: ThinkEquity

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering February 13, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.

            Lead Product(s): ATR-12

            Therapeutic Area: Rare Diseases and Disorders Product Name: ATR-12

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: ThinkEquity

            Deal Size: $7.5 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company intends to use the net proceeds for clinical trials and product development of ATR-12, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of LEKTI protein to treat netherton syndrome.

            Lead Product(s): Strain of Staphylococcus Epidermidis

            Therapeutic Area: Rare Diseases and Disorders Product Name: ATR-12

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: ThinkEquity

            Deal Size: $7.5 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership will focus on developing cutting-edge skin products using engineered and wild-type bacteria for biotherapeutic, over-the-counter and cosmetic applications leveraging Azitra’s technology platform for both live therapeutic products and consumer programs.

            Lead Product(s): ATR-01

            Therapeutic Area: Dermatology Product Name: ATR-01

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Leaps by Bayer

            Deal Size: $17.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing October 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The patent includes broad composition of matter claims that cover the Company’s engineered bacterial strain discovery platform, are central to its programs for treating skin diseases, and provide a significant barrier to entry for competitors.

            Lead Product(s): Recombinant Staphylococcus epidermidis

            Therapeutic Area: Dermatology Product Name: ATR-04

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 07, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            If ATR-12 is approved, Azitra would be eligible to receive a priority review voucher, which can be used for priority review of a drug marketing application for another product being developed by the company.

            Lead Product(s): ATR-12

            Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY